Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GYRE
SellFallen FavouriteGyre Therapeutics, Inc. · Healthcare · United States · $699M · Avg Vol: $416K/d
COMPANY DESCRIPTION
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. It leverages its proprietary platform to target key pathways involved in fibrosis, aiming to address significant unmet medical needs in conditions like idiopathic pulmonary fibrosis (IPF). Its specialized focus on complex fibrotic diseases positions it in a high-potential therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.3M | 113.5M | 105.8M | 116.6M | 4.5% | 109.8M | 109.5M | 139.6M | 9.4% |
| EPS | 0.03 | -1.41 | 0.14 | 0.06 | 25.9% | -0.21 | -0.22 | -0.20 | — |
| Shares | 76.6M | 76.6M | 86.3M | 91.3M | +19.2% | 106.0M | — | — | — |
| Debt | 0.6M | 0.4M | 1.6M | 0.9M | 15.3% | 3.4M | — | — | — |
| Equity | 42.5M | -15.8M | 63.3M | 106.0M | 35.6% | — | — | — | — |
| Op CF | 10.7M | 25.9M | -3.6M | 1.0M | -54.4% | -4.9M | — | — | — |
| Inv CF | -13.8M | -19.8M | -19.9M | -0.5M | — | — | — | — | — |
| Fin CF | 0 | 2.5M | 2.1M | 24.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GYRE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GYRE | Gyre Therapeutics, Inc.(you) | $699M | 34 | Sell |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| ASMB | Assembly Biosciences, Inc. | $694M | 31 | Sell |
| SGMT | Sagimet Biosciences Inc. | $656M | 32 | Sell |
| OVID | Ovid Therapeutics Inc. | $547M | 35 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 30 | Sell |
| OABI | OmniAb, Inc. | $650M | 40 | Hold |
| ARTV | Artiva Biotherapeutics, Inc. | $542M | 37 | Hold |
| FTH | Faeth Therapeutics, Inc. | $874M | 30 | Sell |
| ARVN | Arvinas, Inc. | $592M | 40 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%